|
NNT for at least 50% pain relief in dental pain |
||||||||
| Improved with |
Mean percent improved with |
|||||||
|
|
|
|||||||
| Number of trials |
Drug and dose (mg) |
Active |
Placebo |
Relative risk (95% CI) |
NNT (95% CI) |
Placebo |
Active |
|
|
|
||||||||
| Six hours |
||||||||
|
|
||||||||
| 13 |
Rofecoxib 50 mg |
832/1330 |
58/570 |
5.9 (4.6 to 7.5) |
1.9 (1.8 to 2.1) |
10 |
63 |
|
| 6 |
Ibuprofen 400 mg |
159/303 |
25/298 |
6.3 (4.2 to 9.2) |
2.3 (2.0 to 2.7) |
9 |
53 |
|
| 1 |
Diclofenac 50 mg |
32/121 |
8/63 |
2.1 (1.02 to 4.2) |
7.3 (4.0 to 42) |
13 |
26 |
|
| 2 |
Naproxen 550 mg |
52/88 |
9/87 |
5.7 (3.0 to 11) |
2.1 (1.6 to 2.7) |
11 |
59 |
|
| 2 |
Oxycodone 5 mg + paracetamol 325 mg |
30/180 |
5/61 |
2.0 (0.8 to 5.0) |
nc |
8 |
17 |
|
| 2 |
Paracetamol 600 mg + codeine 60 mg |
102/360 |
11/61 |
1.6 (0.9 to 2.7) |
nc |
18 |
28 |
|
|
|
||||||||
| Eight hours |
||||||||
|
|
||||||||
| 13 |
Rofecoxib 50 mg |
814/1330 |
62/570 |
5.4 (4.3 to 6.9) |
2.0 (1.9 to 2.1) |
11 |
61 |
|
| 6 |
Ibuprofen 400 mg |
135/303 |
25/298 |
5.3 (3.6 to 7.9) |
2.8 (2.4 to 3.4) |
8 |
44 |
|
|
|
||||||||
| 1 |
Diclofenac 50 mg |
32/121 |
11/63 |
1.5 (0.8 to 2.8) |
nc |
17 |
26 |
|
| 6 |
Ibuprofen 400 mg |
135/303 |
25/298 |
5.3 (3.6 to 7.9) |
2.8 (2.4 to 3.4) |
8 |
44 |
|
| 2 |
Naproxen 550 mg |
45/88 |
8/87 |
5.6 (2.8 to 11) |
2.4 (1.9 to 3.4) |
10 |
51 |
|
| 2 |
Oxycodone 5 mg + paracetamol 325 mg |
21/180 |
4/61 |
1.8 (0.6 to 5.0) |
nc |
6 |
12 |
|
| 2 |
Paracetamol 600 mg + codeine 60 mg |
70/360 |
10/61 |
1.2 (0.7 to 2.1) |
nc |
16 |
20 |
|
|
|
||||||||
| Twelve hours |
||||||||
|
|
||||||||
| 13 |
Rofecoxib 50 mg |
662/1330 |
46/570 |
5.9 (4.5 to 7.8) |
2.4 (2.2 to 2.6) |
8 |
50 |
|
| 6 |
Ibuprofen 400 mg |
73/303 |
19/298 |
3.8 (2.4 to 6.1) |
5.6 (4.3 to 8.2) |
6 |
24 |
|
| 1 |
Diclofenac 50 mg |
No data – doses repeated every 8 hours |
||||||
| 6 |
Ibuprofen 400 mg |
73/303 |
19/298 |
3.8 (2.4 to 6.1) |
5.6 (4.3 to 8.2) |
6 |
24 |
|
| 2 |
Naproxen 550 mg |
30/88 |
7/87 |
4.2 (2.0 to 9.1) |
3.9 (2.7 to 7.0) |
8 |
34 |
|
| 2 |
Oxycodone 5 mg + paracetamol 325 mg |
15/180 |
2/61 |
2.5 (0.6 to 11) |
nc |
3 |
8 |
|
| 2 |
Paracetamol 600 mg + codeine 60 mg |
30/360 |
8/61 |
0.6 (0.3 to 1.3) |
nc |
13 |
8 |
|
|
|
||||||||
| Twenty-four hours |
||||||||
|
|
||||||||
| 13 |
Rofecoxib 50 mg |
595/1330 |
49/570 |
5.1 (3.9 to 6.7) |
2.8 (2.5 to 3.1) |
9 |
45 |
|
| 6 |
Ibuprofen 400 mg |
43/303 |
21/298 |
2.0 (1.2 to 3.3) |
14 (8.3 to 44) |
7 |
14 |
|
|
|
||||||||
| 1 |
Diclofenac 50 mg |
No data – doses repeated every 8 hours |
||||||
| 6 |
Ibuprofen 400 mg |
43/303 |
21/298 |
2.0 (1.2 to 3.3) |
14 (8.3 to 44) |
7 |
14 |
|
| 2 |
Naproxen 550 mg |
24/88 |
8/87 |
3.0 (1.4 to 6.2) |
5.5 (3.4 to 14) |
9 |
27 |
|
| 2 |
Oxycodone 5 mg + paracetamol 325 mg |
18/1804 |
61 |
1.4 (0.5 to 3.6) |
nc |
7 |
10 |
|
| 2 |
Paracetamol 600 mg + codeine 60 mg |
24/360 |
7/61 |
0.6 (0.3 to 1.2) |
nc |
11 |
7 |
|
|
nc: not calculated because relative risk showed no statistically significant difference between active and placebo. Naproxen was given as the sodium salt | ||||||||
Edwards et al. BMC Anesthesiology 2004 4:3 doi:10.1186/1471-2253-4-3 |
||||||||